Medical Imaging-Pathology-Genomic Fusion and Its Applications in Clinical Diagnosis and Treatment
CSTR:
Author:
Affiliation:

1Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China;2State Key Laboratory of Medical Imaging Science and Technology Systems, Shenzhen 518055, China;3Institute of Brain Machine Interface, Nanjing University, Nanjing 210023, China

Clc Number:

R3

Fund Project:

Shenzhen Medical Research Fund (No.A2303008); National Natural Science Foundation of China (Nos.T2525037, 62201557, 62571523);Guangdong Special Support Plan (No.2024TX08A213); Shenzhen Science and Technology Program (Nos.JCYJ20250604183020027, JCYJ20241202125014018); Strategic Priority Research Program of the Chinese Academy of Sciences (No.XDB0930302).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Medical imaging, pathology, and genomics respectively provide information on tumor spatial-morphological phenotypes, histopathological architecture, and molecular mechanisms. Single-modal approaches are constrained by scale discrepancies, sampling biases, and cross-center domain shifts, limiting their support for clinical decision-making. For precision oncology, imaging-pathology-genomics integration aims at semantical alignment and consistency validation among macroscopic imaging, microscopic histological, and mechanistic molecular evidence. This review systematically examines the field via fusion methodologies and clinical applications. We discuss the clinical advantages of multimodal integration, summarize key fusion paradigms, and emphasize its clinical necessity. In applications, focusing on completing the clinical evidence chain, we summarize its advantages in differential diagnosis, molecular subtyping, surgical planning, treatment response stratification, and systematic decision output, highlighting how integration turns predictive results into verifiable, actionable clinical decisions via cross-modal validation. Finally, we discuss emerging trends: spatial omics with multi-region sampling, longitudinal tumor evolution modeling, multimodal foundation models, and multi-center collaborative validation. We propose clinical translation recommendations and a utility evaluation system, offering a roadmap for next-generation intelligent multimodal systems in precision oncology.Highlights 1. Imaging-pathology-genomics integration completes the clinical evidence chain by fusing macroscopic, microscopic, and molecular evidence. It transforms fragmented observations into cohesive tumor biology understanding and enables verifiable, actionable decisions, beyond simple feature aggregation.2. Fusion paradigms integrate into oncology workflows: differential diagnosis, molecular subtyping, surgical planning, treatment response stratification, and standardized reporting integrating multimodal predictions into decisions.3. Emerging advances shape next-generation systems: spatial omics with multi-region sampling, longitudinal modeling, multimodal foundation models, and multi-center validation. Combined with translation guidelines and evaluation systems, they provide a deployment roadmap.

    Reference
    Related
    Cited by
Get Citation

DUAN Jingxian, ZHAO Yuanshen, KANG Liangyuqi, LIANG Dong, ZHENG Hairong, LI Zhicheng. Medical Imaging-Pathology-Genomic Fusion and Its Applications in Clinical Diagnosis and Treatment[J]. Journal of Data Acquisition and Processing,2026,(2):416-438.

Copy
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:January 09,2026
  • Revised:March 11,2026
  • Adopted:
  • Online: April 15,2026
  • Published:
Article QR Code